<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>M2950303.DOC;1</TITLE>
<META NAME="author" CONTENT="GFernandez">
<META NAME="date" CONTENT="01/15/2013">
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<A NAME="Macro_Start"></A><DIV style="width:624px"><P style="margin-top:0px; margin-bottom:16px; font-size:12pt" align=center>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
WASHINGTON, D.C. 20549</P>
<P style="margin-top:0px; margin-bottom:16px; font-size:12pt" align=center>FORM 8-K</P>
<P style="margin-top:0px; margin-bottom:16px; font-size:12pt" align=center>CURRENT REPORT PURSUANT<BR>
TO SECTION 13 or 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</P>
<P style="margin-top:0px; margin-bottom:16px; font-size:12pt" align=center>Date of report (Date of earliest event reported): &nbsp;December 31, 2012</P>
<P style="margin-top:0px; margin-bottom:16px; font-size:12pt" align=center>Medytox Solutions, Inc.<BR>
(Exact Name of Registrant as Specified in Its Charter)</P>
<P style="margin-top:0px; margin-bottom:16px; font-size:12pt" align=center>Nevada<BR>
(State or Other Jurisdiction of Incorporation)</P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 align=center><TR height=0 style="font-size:0"><TD width=290 /><TD width=326 /></TR>
<TR><TD style="margin-top:0px" valign=top width=290><P style="margin:0px; font-size:12pt" align=center>000-54346</P>
</TD><TD style="margin-top:0px" valign=top width=326><P style="margin:0px; font-size:12pt" align=center>54-2156042</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=290><P style="margin:0px; font-size:12pt" align=center>(Commission File Number)</P>
</TD><TD style="margin-top:0px" valign=top width=326><P style="margin:0px; font-size:12pt" align=center>(I.R.S. Employer Identification No.)</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 width=100%><TR height=0 style="font-size:0"><TD /><TD width=138 /></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px; font-size:12pt" align=center>400 S. Australian Avenue, Suite 800, West Palm Beach, Florida</P>
</TD><TD style="margin-top:0px" valign=top width=138><P style="margin:0px; font-size:12pt" align=center>33401</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px; font-size:12pt" align=center>(Address of Principal Executive Offices)</P>
</TD><TD style="margin-top:0px" valign=top width=138><P style="margin:0px; font-size:12pt" align=center>(Zip Code)</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=618 /></TR>
<TR><TD style="margin-top:0px" valign=top width=618><P style="margin:0px; font-size:12pt" align=center>(561) 855-1626</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=618><P style="margin:0px; font-size:12pt" align=center>(Registrant&#146;s Telephone Number, Including Area Code)</P>
</TD></TR>
</TABLE>
<P style="margin-top:0px; margin-bottom:16px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=618 /></TR>
<TR><TD style="margin-top:0px" valign=top width=618><P style="margin:0px; padding:0px">&nbsp;</P></TD></TR>
<TR><TD style="margin-top:0px" valign=top width=618><P style="margin:0px; font-size:12pt" align=center>(Former Name or Former Address, if Changed Since Last Report)</P>
</TD></TR>
</TABLE>
<P style="margin-top:0px; margin-bottom:16px"><BR></P>
<P style="margin-top:0px; margin-bottom:16px; font-size:12pt" align=justify>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</P>
<P style="margin-top:0px; margin-bottom:16px; font-family:Wingdings; font-size:12pt" align=justify>o<FONT style="font-family:Times New Roman"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
<P style="margin-top:0px; margin-bottom:16px; font-family:Wingdings; font-size:12pt" align=justify>o<FONT style="font-family:Times New Roman"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>
<P style="margin-top:0px; margin-bottom:16px; font-family:Wingdings; font-size:12pt" align=justify>o<FONT style="font-family:Times New Roman"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>
<P style="margin-top:0px; margin-bottom:16px; font-family:Wingdings; font-size:12pt" align=justify>o<FONT style="font-family:Times New Roman"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>
<P style="margin-top:0px; margin-bottom:16px"><BR>
<BR></P>
<P style="margin-top:0px; margin-bottom:16px; font-size:12pt; page-break-before:always"><B>Section 5 <font style='font-family:Arial Unicode MS,Times New Roman'>&#8211;</font> Corporate Governance and Management</B></P>
<P style="margin-top:0px; margin-bottom:16px; text-indent:48px; font-size:12pt"><B>Item 5.02. &nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</B></P>
<P style="margin-top:0px; margin-bottom:16px; text-indent:48px; font-size:12pt" align=justify>Effective December&nbsp;31, 2012, each of Joseph Fahoome and Robert Kuechenberg resigned from the Board of Directors of Medytox Solutions, Inc. (the &quot;Company&quot;). &nbsp;Neither Mr. Fahoome nor Mr. Kuechenberg expressed any disagreement with the Company on any matter relating to the Company's operations, policies or practices. &nbsp;The Company granted to each of Mr. Fahoome and Mr. Kuechenberg options to purchase 10,000 shares of the Company's common stock, par value $.0001 per share, exercisable at $2.50 a share through December 31, 2014, pursuant to the terms of their respective option agreements. &nbsp;</P>
<P style="margin-top:0px; margin-bottom:16px; text-indent:48px; font-size:12pt" align=justify>The foregoing is qualified in its entirety by reference to (i) the Option Agreement between the Company and Joseph Fahoome, a copy of which is filed herewith as Exhibit 10.1, and (ii) the Option Agreement between the Company and Robert Kuechenberg, a copy of which is filed herewith as Exhibit 10.2.</P>
<P style="margin-top:0px; margin-bottom:16px; font-size:12pt"><B>Section 9 &#150; Financial Statements and Exhibits</B></P>
<P style="margin-top:0px; margin-bottom:16px; padding-left:48px; font-size:12pt"><B>Item 9.01. Financial Statements and Exhibits</B></P>
<P style="margin-top:0px; margin-bottom:16px; text-indent:48px; font-size:12pt" align=justify>(d) &nbsp;Exhibits</P>
</DIV><TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=319.2 /><TD width=319.2 /></TR>
<TR><TD style="margin-top:0px" valign=top width=319.2><P style="margin-top:6.667px; margin-bottom:6.667px; font-size:12pt" align=center><U>Exhibit Number</U></P>
</TD><TD style="margin-top:0px" valign=top width=319.2><P style="margin-top:6.667px; margin-bottom:6.667px; font-size:12pt" align=center><U>Description</U></P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=319.2><P style="margin-top:6.667px; margin-bottom:6.667px; font-size:12pt" align=center>10.1</P>
</TD><TD style="margin-top:0px" valign=top width=319.2><P style="margin:0px; font-size:12pt">Option Agreement, dated as of December&nbsp;31, 2012, between Joseph Fahoome and Medytox Solutions, Inc.</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=319.2><P style="margin-top:6.667px; margin-bottom:6.667px; font-size:12pt" align=center>10.2</P>
</TD><TD style="margin-top:0px" valign=top width=319.2><P style="margin:0px; font-size:12pt">Option Agreement, dated as of December&nbsp;31, 2012, between Robert Kuechenberg and Medytox Solutions, Inc.</P>
</TD></TR>
</TABLE>
<DIV style="width:624px"><P style="margin-top:0px; margin-bottom:32px" align=center><BR>
<BR></P>
<P style="margin:0px; text-indent:310.333px" align=justify>2</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin-top:0px; margin-bottom:32px; font-size:12pt; page-break-before:always" align=center><B>SIGNATURES</B></P>
<P style="margin-top:0px; margin-bottom:48px; text-indent:48px; font-size:12pt" align=justify>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </P>
<P style="margin-top:0px; margin-bottom:-2px; width:336px; font-size:12pt; float:left">Date: &nbsp;January 14, 2013</P>
<P style="margin:0px; text-indent:-2px; font-size:12pt">MEDYTOX SOLUTIONS, INC.</P>
<P style="margin:0px; clear:left"><BR></P>
<P style="margin:0px; text-indent:336px; font-size:12pt"><U>/s/ William G. Forhan</U></P>
<P style="margin-top:0px; margin-bottom:16px; padding-left:336px; font-size:12pt">William G. Forhan,<BR>
CEO and Chairman<BR>
(principal executive officer)</P>
<P style="margin-top:0px; margin-bottom:16px" align=justify><BR></P>
<P style="margin:0px; font-size:12pt">&nbsp;</P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; text-indent:310.333px" align=justify>3</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin-top:0px; margin-bottom:32px; font-size:12pt; page-break-before:always" align=center><B>EXHIBIT INDEX</B></P>
</DIV><TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=319.2 /><TD width=319.2 /></TR>
<TR><TD style="margin-top:0px" valign=top width=319.2><P style="margin-top:6.667px; margin-bottom:6.667px; font-size:12pt" align=center><U>Exhibit Number</U></P>
</TD><TD style="margin-top:0px" valign=top width=319.2><P style="margin-top:6.667px; margin-bottom:6.667px; font-size:12pt" align=center><U>Description</U></P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=319.2><P style="margin-top:6.667px; margin-bottom:6.667px; font-size:12pt" align=center>10.1</P>
</TD><TD style="margin-top:0px" valign=top width=319.2><P style="margin:0px; font-size:12pt">Option Agreement, dated as of December&nbsp;31, 2012, between Joseph Fahoome and Medytox Solutions, Inc.</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=319.2><P style="margin-top:6.667px; margin-bottom:6.667px; font-size:12pt" align=center>10.2</P>
</TD><TD style="margin-top:0px" valign=top width=319.2><P style="margin:0px; font-size:12pt">Option Agreement, dated as of December&nbsp;31, 2012, between Robert Kuechenberg and Medytox Solutions, Inc.</P>
</TD></TR>
</TABLE>
<DIV style="width:624px"><P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify><BR>
<BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: F3D1769A -->
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "msi8k011413.htm", "secsgml_size_bytes": 11101}]
{"company-data": {"conformed-name": "Medytox Solutions, Inc.", "cik": "0001374536", "assigned-sic": "8734", "irs-number": "542156042", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-54346", "film-number": "13531067"}, "business-address": {"street1": "400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR", "city": "WEST PALM BEACH", "state": "FL", "zip": "33401", "phone": "(561) 855-1626"}, "mail-address": {"street1": "400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR", "city": "WEST PALM BEACH", "state": "FL", "zip": "33401"}, "former-company": {"former-conformed-name": "CASINO PLAYERS, INC.", "date-changed": "20060905"}}
M2950303.DOC;1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):  December 31, 2012
Medytox Solutions, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Nevada
(State or Other Jurisdiction of Incorporation)
000-54346
54-2156042
(Commission File Number)
(I.R.S. Employer Identification No.)
400 S. Australian Avenue, Suite 800, West Palm Beach, Florida
33401
(Address of Principal Executive Offices)
(Zip Code)
(561) 855-1626
(Registrant's Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 5
–
Corporate Governance and Management
Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Effective December 31, 2012, each of Joseph Fahoome and Robert Kuechenberg resigned from the Board of Directors of Medytox Solutions, Inc. (the "Company").  Neither Mr. Fahoome nor Mr. Kuechenberg expressed any disagreement with the Company on any matter relating to the Company's operations, policies or practices.  The Company granted to each of Mr. Fahoome and Mr. Kuechenberg options to purchase 10,000 shares of the Company's common stock, par value $.0001 per share, exercisable at $2.50 a share through December 31, 2014, pursuant to the terms of their respective option agreements.
The foregoing is qualified in its entirety by reference to (i) the Option Agreement between the Company and Joseph Fahoome, a copy of which is filed herewith as Exhibit 10.1, and (ii) the Option Agreement between the Company and Robert Kuechenberg, a copy of which is filed herewith as Exhibit 10.2.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits
(d)  Exhibits
Exhibit Number
Description
10.1
Option Agreement, dated as of December 31, 2012, between Joseph Fahoome and Medytox Solutions, Inc.
10.2
Option Agreement, dated as of December 31, 2012, between Robert Kuechenberg and Medytox Solutions, Inc.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:  January 14, 2013
MEDYTOX SOLUTIONS, INC.
/s/ William G. Forhan
William G. Forhan,
CEO and Chairman
(principal executive officer)
3
EXHIBIT INDEX
Exhibit Number
Description
10.1
Option Agreement, dated as of December 31, 2012, between Joseph Fahoome and Medytox Solutions, Inc.
10.2
Option Agreement, dated as of December 31, 2012, between Robert Kuechenberg and Medytox Solutions, Inc.